Deals channel feed – Endpoints News

Deals channel feed

Bristol Myers wants to pull out of its Abraxane deal in China. BeiGene says no way

4 years ago

Charles River Laboratories has been on an acquisition spree. But Tuesday, it offloaded two assets

4 years ago

Drawn to the idea of turning B cells into 'protein factories,' Takeda jumps into a milestone-heavy, $900M pact

4 years ago

Intellia enters Editas’ turf with ocular CRISPR pact

4 years ago

GSK tangoes with private equity players to explore $54B sale of consumer unit instead of IPO — report

4 years ago

Inside the deal: As leaked details goosed its stock, Acceleron's CEO pumped Merck for more cash

4 years ago

Takeda enlists Poseida in $3.6B+ nonviral gene therapy deal, though data remain years away from human studies

4 years ago

Aceto keeps up spending spree with acquisition of Ireland's A&C

4 years ago

Supernus expands its portfolio of Parkinson's drugs with a $400M+ buyout

4 years ago

Flexion heads to the discount aisle for a $450M+ merger with Pacira

4 years ago

Lumen lands another DoD contract to treat Covid-related GI issues

4 years ago

As continent's vaccination rate sits below 5%, Moderna announces investment in mRNA manufacturing in Africa

4 years ago

Science 37 takes the SPAC shortcut to Nasdaq, landing a $235M windfall for its push on decentralized trials

4 years ago

Is the biotech boom starting to fade? The roaring ‘20s starts to look a little fatigued. Plus: Top 5 deals, IPOs, pacts of Q3

4 years ago

Troubled Voyager’s gene therapy relaunch gets a boost with $630M Pfizer deal

4 years ago

Has Selecta found a way around gene therapy's delivery problem? Takeda puts down $1B-plus to find out

4 years ago

J&J signs on Xencor for a $100M licensing deal targeting CD20, looking to press its advantage in bispecifics

4 years ago

Emergent lands another big money contract from BARDA for anthrax

4 years ago

Otsuka puts nearly $1 billion on the line for four neuropsychiatric candidates from Sunovion

4 years ago

Merck, wading even further into rare disease, inks $11.5B deal for Acceleron and its potential PAH blockbuster

4 years ago

I-Mab in talks about deals, stake sale to build on $3B AbbVie alliance — Bloomberg

4 years ago

AstraZeneca wagers on $500M buyout, plucks PhIII drug for Alexion’s rare disease pipeline — and jumps straight into risky field

4 years ago

Banking on integrase inhibitors as HIV cornerstone, ViiV bags 3rd-generation compound from Shionogi

4 years ago

Innovent bets $250M+ on Union's PDE4 inhibitor ahead of a PhII readout

4 years ago

First page Previous page 68 69 707172 73 74 Next page Last page